These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1358 related articles for article (PubMed ID: 28389661)

  • 1. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
    Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
    Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 3. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
    Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
    Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H; Lei W; Zhang C; Yang C; Wei J; Guo Q; Guo X; Chen Z; Lu Y; Young KH; Lu Z; Qian W
    Clin Cancer Res; 2021 Jan; 27(2):473-484. PubMed ID: 33028589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.
    Hu W; Zi Z; Jin Y; Li G; Shao K; Cai Q; Ma X; Wei F
    Cancer Immunol Immunother; 2019 Mar; 68(3):365-377. PubMed ID: 30523370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
    Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A versatile system for rapid multiplex genome-edited CAR T cell generation.
    Ren J; Zhang X; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Oncotarget; 2017 Mar; 8(10):17002-17011. PubMed ID: 28199983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness.
    Lau E; Kwong G; Fowler TW; Sun BC; Donohoue PD; Davis RT; Bryan M; McCawley S; Clarke SC; Williams C; Banh L; Irby M; Edwards L; Storlie M; Kohrs B; Lilley GWJ; Smith SC; Gradia S; Fuller CK; Skoble J; Garner E; van Overbeek M; Kanner SB
    Cytotherapy; 2023 Jul; 25(7):750-762. PubMed ID: 37086241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition.
    Andreu-Saumell I; Rodriguez-Garcia A; Mühlgrabner V; Gimenez-Alejandre M; Marzal B; Castellsagué J; Brasó-Maristany F; Calderon H; Angelats L; Colell S; Nuding M; Soria-Castellano M; Barbao P; Prat A; Urbano-Ispizua A; Huppa JB; Guedan S
    Nat Commun; 2024 Apr; 15(1):3552. PubMed ID: 38670972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro.
    Liu M; Wang X; Li Z; Zhang R; Mu J; Jiang Y; Deng Q; Sun L
    Cancer Sci; 2020 Nov; 111(11):4051-4060. PubMed ID: 32876369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
    Chang ZL; Silver PA; Chen YY
    J Transl Med; 2015 May; 13():161. PubMed ID: 25990251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
    Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
    Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition.
    Ren J; Liu X; Fang C; Jiang S; June CH; Zhao Y
    Clin Cancer Res; 2017 May; 23(9):2255-2266. PubMed ID: 27815355
    [No Abstract]   [Full Text] [Related]  

  • 16. Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
    Toews K; Grunewald L; Schwiebert S; Klaus A; Winkler A; Ali S; Zirngibl F; Astrahantseff K; Wagner DL; Henssen AG; Deubzer HE; Schulte JH; Ochsenreither S; Eggert A; Künkele A
    Mol Carcinog; 2020 Jul; 59(7):724-735. PubMed ID: 32333465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
    Liao Y; Chen L; Feng Y; Shen J; Gao Y; Cote G; Choy E; Harmon D; Mankin H; Hornicek F; Duan Z
    Oncotarget; 2017 May; 8(18):30276-30287. PubMed ID: 28415820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody.
    Cheng K; Feng X; Chai Z; Wang Z; Liu Z; Yan Z; Wang Y; Zhang S
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft.
    Zhou JE; Yu J; Wang Y; Wang H; Wang J; Wang Y; Yu L; Yan Z
    Biomed Pharmacother; 2021 May; 137():111339. PubMed ID: 33550044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.